Development of a Neutralizing Antibody Assay to support Clinical Trials

Frontage supported a Sponsor that required development of a Neutralizing Antibody (NAB) method for an antibody drug that interrupts a Ligand: Receptor interaction.Previous attempts to develop a Cell-Based NAB had been unsuccessful and current attempts to develop a Competitive Ligand Binding assay were also having difficulty with method sensitivity, reproducibility and drug tolerance. Pipeline progression for this asset was halted until these issues could be resolved.